$RNA
Avidity Biosciences, Inc. Stock $rna

$rna Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000159990124000186 Filed on November 07, 2024

Income Statement

Concept	2024 Q4	2024 Q3
Revenue		$2.336M
YoY Change		-17.1%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin		$23.27M
YoY Change		69.5%
% of Gross Profit
Research & Development		$77.20M
YoY Change		61.79%
% of Gross Profit
Depreciation & Amortization		$700.0K
YoY Change		16.67%
% of Gross Profit
Operating Expenses		$100.5M
YoY Change		63.52%
Operating Profit		-$98.13M
YoY Change		67.39%
Interest Expense		$17.97M
YoY Change		186.11%
% of Operating Profit
Other Income/Expense, Net		$17.74M
YoY Change		183.01%
Pretax Income		-$80.40M
YoY Change		53.55%
Income Tax
% Of Pretax Income
Net Earnings		-$80.40M
YoY Change		53.55%
Net Earnings / Revenue		-3441.7%
Basic Earnings Per Share		-$0.65
Diluted Earnings Per Share		-$0.65
COMMON SHARES
Basic Shares Outstanding	119.3M shares	109.8M shares
Diluted Shares Outstanding		123.4M shares

Balance Sheet

Concept	2024 Q4	2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments		$1.589B
YoY Change		192.77%
Cash & Equivalents		$370.2M
Short-Term Investments		$1.218B
Other Short-Term Assets		$33.27M
YoY Change		157.93%
Inventory
Prepaid Expenses		$14.06M
Receivables		$0.00
Other Receivables		$0.00
Total Short-Term Assets		$1.622B
YoY Change		191.97%
LONG-TERM ASSETS
Property, Plant & Equipment		$9.493M
YoY Change		16.77%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets		$318.0K
YoY Change		-7.56%
Total Long-Term Assets		$18.91M
YoY Change		6.95%
TOTAL ASSETS
Total Short-Term Assets		$1.622B
Total Long-Term Assets		$18.91M
Total Assets		$1.641B
YoY Change		186.27%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$7.662M
YoY Change		38.05%
Accrued Expenses		$64.01M
YoY Change		55.37%
Deferred Revenue		$19.66M
YoY Change		898.98%
Short-Term Debt		$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities		$91.33M
YoY Change		87.48%
LONG-TERM LIABILITIES
Long-Term Debt		$0.00
YoY Change
Other Long-Term Liabilities		$46.06M
YoY Change		557.97%
Total Long-Term Liabilities		$46.06M
YoY Change		557.97%
TOTAL LIABILITIES
Total Short-Term Liabilities		$91.33M
Total Long-Term Liabilities		$46.06M
Total Liabilities		$137.4M
YoY Change		146.68%
SHAREHOLDERS EQUITY
Retained Earnings		-$790.8M
YoY Change		54.97%
Common Stock		$2.287B
YoY Change		122.12%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity		$1.503B
YoY Change
Total Liabilities & Shareholders Equity		$1.641B
YoY Change		186.27%

Cashflow Statement

Concept	2024 Q4	2024 Q3
OPERATING ACTIVITIES
Net Income		-$80.40M
YoY Change		53.55%
Depreciation, Depletion And Amortization		$700.0K
YoY Change		16.67%
Cash From Operating Activities		-$65.62M
YoY Change		78.3%
INVESTING ACTIVITIES
Capital Expenditures		$1.704M
YoY Change		83.23%
Acquisitions
YoY Change
Other Investing Activities		-$480.7M
YoY Change		1473.0%
Cash From Investing Activities		-$482.4M
YoY Change		1432.44%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		342.5M
YoY Change		856060.0%
NET CHANGE
Cash From Operating Activities		-65.62M
Cash From Investing Activities		-482.4M
Cash From Financing Activities		342.5M
Net Change In Cash		-205.6M
YoY Change		201.24%
FREE CASH FLOW
Cash From Operating Activities		-$65.62M
Capital Expenditures		$1.704M
Free Cash Flow		-$67.32M
YoY Change		78.42%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Address Address Line1 EntityAddressAddressLine1	10578 Science Center Drive
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity Registrant Name EntityRegistrantName	Avidity Biosciences, Inc.
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92121
	dei	City Area Code CityAreaCode	858
	dei	Local Phone Number LocalPhoneNumber	401-7900
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	6299000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	8271000	usd
CY2024Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	318000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	301000	usd
CY2024Q3	us-gaap	Assets Assets	1640771000	usd
CY2023Q4	us-gaap	Assets Assets	628555000	usd
CY2024Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	49628000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	34341000	usd
CY2024Q3	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	18241000	usd
CY2023Q4	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	14335000	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3804000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3639000	usd
CY2024Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	19660000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	28365000	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	91333000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	80680000	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3797000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	6213000	usd
CY2024Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	42261000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	40898000	usd
CY2024Q3	us-gaap	Liabilities Liabilities	137391000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	127791000	usd
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	118900000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	79275000	shares
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	12000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	8000	usd
CY2024Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	7102000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	125000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-790810000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-570764000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	1503380000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	500764000	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1640771000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	628555000	usd
CY2024Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2336000	usd
CY2024Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	77197000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	47714000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	207968000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	138151000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	57902000	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	61443000	usd
	us-gaap	Operating Expenses OperatingExpenses	265870000	usd
	us-gaap	Operating Expenses OperatingExpenses	176222000	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-98134000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-58625000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-257946000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-168855000	usd
CY2024Q3	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	17968000	usd
	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	17567000	usd
CY2024Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-232000	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-13000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-449000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-489000	usd
CY2024Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	17736000	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	6267000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	37901000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	500764000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3896000	usd
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
CY2024Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	2795000	usd
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	295000	usd
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	79275000	shares
CY2024Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	2287076000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2818000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7924000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7367000	usd
CY2024Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	23273000	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13729000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	38071000	usd
CY2024Q3	us-gaap	Operating Expenses OperatingExpenses	100470000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	17078000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-52358000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-151777000	usd
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.08
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.08
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.11
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	105902000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	71987000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	71987000	shares
CY2024Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	7555000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	788000	usd
CY2024Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-72843000	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-51570000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	14308000	usd
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1071395000	usd
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.11
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	123375000	shares
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	820000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-213068000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10306000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-68855000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-589000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	830899000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-70793000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	11000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	1221036000	usd
	dei	Entity Central Index Key EntityCentralIndexKey	0001599901
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-1336960
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 125
	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value
	dei	Trading Symbol TradingSymbol	RNA
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	119309317	shares
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	370187000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	185082000	usd
CY2024Q3	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest Current DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent	1218406000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest Current DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent	410269000	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	33273000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	15956000	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	1621866000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	611307000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9493000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8381000	usd
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	118900000	shares
CY2023Q3	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	6280000	usd
	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	38350000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-80398000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-220045000	usd
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.65
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.65
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.71
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.71
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	123375000	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	74097000	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	74097000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	105902000	shares
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	6977000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-150957000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1027000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	12812000	usd
CY2024Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	17363000	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	14092000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-80398000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	7555000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	1503380000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	578075000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	520000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	9104000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-52394000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1169000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	558915000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	7000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	859000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	9453000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-47025000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-1137000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	559178000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	40000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	9820000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-52358000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	788000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	517468000	usd
	us-gaap	Profit Loss ProfitLoss	-220045000	usd
	us-gaap	Profit Loss ProfitLoss	-151777000	usd
	us-gaap	Depreciation Depreciation	2038000	usd
	us-gaap	Depreciation Depreciation	1486000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	37210000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	28377000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	14281000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	8037000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	2473000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	2154000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	16928000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	435000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	14722000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-588000	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	3906000	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-25000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-2752000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-2412000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-7342000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-4308000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-200999000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-135565000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	349655000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	229450000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	1136534000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	407195000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3150000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3365000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-790029000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-181110000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	762661000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	60547000	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	36189000	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	1426000	usd
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	238388000	usd
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0	usd
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	141395000	usd
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	0	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1178633000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	61973000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	187605000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-254702000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	185377000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	340647000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	372982000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	85945000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1741000	usd
	rna	Deferred Financing Costs Incurred But Not Yet Paid DeferredFinancingCostsIncurredButNotYetPaid	565000	usd
	rna	Deferred Financing Costs Incurred But Not Yet Paid DeferredFinancingCostsIncurredButNotYetPaid	0	usd
	rna	Noncash Transaction Proceeds From Stock Options Exercised NoncashTransactionProceedsFromStockOptionsExercised	406000	usd
	rna	Noncash Transaction Proceeds From Stock Options Exercised NoncashTransactionProceedsFromStockOptionsExercised	0	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	655000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	238000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-790800000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	1600000000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s condensed consolidated financial statements are prepared in accordance with GAAP, which requires the Company to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the condensed consolidated financial statements and accompanying notes. The most significant estimates in the Company’s condensed consolidated financial statements relate to revenue recognition, stock-based compensation, and accrued research and development costs. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</span></div>
CY2024Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14198000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14198000	shares
CY2023Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14086000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14086000	shares
CY2024Q3	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss	1211304000	usd
CY2024Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	7147000	usd
CY2024Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	45000	usd
CY2024Q3	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	1218406000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss	410144000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	703000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	578000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	410269000	usd
CY2024Q3	us-gaap	Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest	0	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest	0	usd
CY2024Q3	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	30920000	usd
CY2024Q3	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	21000	usd
CY2024Q3	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	34413000	usd
CY2024Q3	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	24000	usd
CY2024Q3	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	65333000	usd
CY2024Q3	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	45000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	222954000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	578000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	0	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	0	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	222954000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	578000	usd
CY2024Q3	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss	8300000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss	2600000	usd
	us-gaap	Debt Securities Available For Sale Accrued Interest Writeoff DebtSecuritiesAvailableForSaleAccruedInterestWriteoff	0	usd
	us-gaap	Debt Securities Available For Sale Accrued Interest Writeoff DebtSecuritiesAvailableForSaleAccruedInterestWriteoff	0	usd
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	69263000	usd
CY2024Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	2961000	usd
CY2024Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	66302000	usd
CY2024Q2	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	2045000	usd
CY2024Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	64257000	usd
CY2024Q3	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	2336000	usd
CY2024Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	61921000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	6276000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	1219000	usd
CY2023Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	5057000	usd
CY2023Q2	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	1247000	usd
CY2023Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	3810000	usd
CY2023Q3	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	1842000	usd
CY2023Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	1968000	usd
CY2024Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	0	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1105000	usd
CY2024Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	14063000	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	7333000	usd
CY2024Q3	rna	Interest Receivable And Other Assets Current InterestReceivableAndOtherAssetsCurrent	19210000	usd
CY2023Q4	rna	Interest Receivable And Other Assets Current InterestReceivableAndOtherAssetsCurrent	7518000	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	33273000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	15956000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	16752000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	13602000	usd
CY2024Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7259000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5221000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9493000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8381000	usd
CY2024Q3	us-gaap	Depreciation Depreciation	700000	usd
CY2023Q3	us-gaap	Depreciation Depreciation	600000	usd
	us-gaap	Depreciation Depreciation	2000000.0	usd
	us-gaap	Depreciation Depreciation	1500000	usd
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	7662000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8809000	usd
CY2024Q3	rna	Accrued Non Clinical Liabilities Current AccruedNonClinicalLiabilitiesCurrent	35622000	usd
CY2023Q4	rna	Accrued Non Clinical Liabilities Current AccruedNonClinicalLiabilitiesCurrent	19535000	usd
CY2024Q3	rna	Accrued Clinical Liabilities Current AccruedClinicalLiabilitiesCurrent	6344000	usd
CY2023Q4	rna	Accrued Clinical Liabilities Current AccruedClinicalLiabilitiesCurrent	5997000	usd
CY2024Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	49628000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	34341000	usd
CY2024Q3	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	0	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	12495000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	14.91
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2903000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	21.81
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	2749000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	12.94
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	459000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	14.53
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	12190000	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	17.01
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2024Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	14092000	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9820000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	37210000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	28377000	usd
CY2024Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	79300000	usd
CY2024Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001599901-24-000186-index-headers.html	Edgar Link	pending
0001599901-24-000186-index.html	Edgar Link	pending
0001599901-24-000186.txt	Edgar Link	pending
0001599901-24-000186-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rna-20240930.htm	Edgar Link	pending
rna-20240930.xsd	Edgar Link	pending
rna-20240930xex102amende.htm	Edgar Link	pending
rna-20240930xex102amende001.jpg	Edgar Link	pending
rna-20240930xex102amende002.jpg	Edgar Link	pending
rna-20240930xex102amende003.jpg	Edgar Link	pending
rna-20240930xex102amende004.jpg	Edgar Link	pending
rna-20240930xex102amende005.jpg	Edgar Link	pending
rna-20240930xex102amende006.jpg	Edgar Link	pending
rna-20240930xex102amende007.jpg	Edgar Link	pending
rna-20240930xex102amende008.jpg	Edgar Link	pending
rna-20240930xex102amende009.jpg	Edgar Link	pending
rna-20240930xex102amende010.jpg	Edgar Link	pending
rna-20240930xex102amende011.jpg	Edgar Link	pending
rna-20240930xex102amende012.jpg	Edgar Link	pending
rna-20240930xex102amende013.jpg	Edgar Link	pending
rna-20240930xex103amende.htm	Edgar Link	pending
rna-20240930xex103amende001.jpg	Edgar Link	pending
rna-20240930xex103amende002.jpg	Edgar Link	pending
rna-20240930xex103amende003.jpg	Edgar Link	pending
rna-20240930xex103amende004.jpg	Edgar Link	pending
rna-20240930xex103amende005.jpg	Edgar Link	pending
rna-20240930xex103amende006.jpg	Edgar Link	pending
rna-20240930xex103amende007.jpg	Edgar Link	pending
rna-20240930xex103amende008.jpg	Edgar Link	pending
rna-20240930xex103amende009.jpg	Edgar Link	pending
rna-20240930xex103amende010.jpg	Edgar Link	pending
rna-20240930xex103amende011.jpg	Edgar Link	pending
rna-20240930xex103amende012.jpg	Edgar Link	pending
rna-20240930xex103amende013.jpg	Edgar Link	pending
rna-20240930xex104amende.htm	Edgar Link	pending
rna-20240930xex104amende001.jpg	Edgar Link	pending
rna-20240930xex104amende002.jpg	Edgar Link	pending
rna-20240930xex104amende003.jpg	Edgar Link	pending
rna-20240930xex104amende004.jpg	Edgar Link	pending
rna-20240930xex104amende005.jpg	Edgar Link	pending
rna-20240930xex104amende006.jpg	Edgar Link	pending
rna-20240930xex104amende007.jpg	Edgar Link	pending
rna-20240930xex104amende008.jpg	Edgar Link	pending
rna-20240930xex104amende009.jpg	Edgar Link	pending
rna-20240930xex104amende010.jpg	Edgar Link	pending
rna-20240930xex104amende011.jpg	Edgar Link	pending
rna-20240930xex104amende012.jpg	Edgar Link	pending
rna-20240930xex104amende013.jpg	Edgar Link	pending
rna-20240930xex105amende.htm	Edgar Link	pending
rna-20240930xex105amende001.jpg	Edgar Link	pending
rna-20240930xex105amende002.jpg	Edgar Link	pending
rna-20240930xex105amende003.jpg	Edgar Link	pending
rna-20240930xex105amende004.jpg	Edgar Link	pending
rna-20240930xex105amende005.jpg	Edgar Link	pending
rna-20240930xex105amende006.jpg	Edgar Link	pending
rna-20240930xex105amende007.jpg	Edgar Link	pending
rna-20240930xex105amende008.jpg	Edgar Link	pending
rna-20240930xex105amende009.jpg	Edgar Link	pending
rna-20240930xex105amende010.jpg	Edgar Link	pending
rna-20240930xex105amende011.jpg	Edgar Link	pending
rna-20240930xex105amende012.jpg	Edgar Link	pending
rna-20240930xex106amende.htm	Edgar Link	pending
rna-20240930xex106amende001.jpg	Edgar Link	pending
rna-20240930xex106amende002.jpg	Edgar Link	pending
rna-20240930xex106amende003.jpg	Edgar Link	pending
rna-20240930xex106amende004.jpg	Edgar Link	pending
rna-20240930xex106amende005.jpg	Edgar Link	pending
rna-20240930xex106amende006.jpg	Edgar Link	pending
rna-20240930xex106amende007.jpg	Edgar Link	pending
rna-20240930xex106amende008.jpg	Edgar Link	pending
rna-20240930xex106amende009.jpg	Edgar Link	pending
rna-20240930xex106amende010.jpg	Edgar Link	pending
rna-20240930xex106amende011.jpg	Edgar Link	pending
rna-20240930xex106amende012.jpg	Edgar Link	pending
rna-20240930xex106amende013.jpg	Edgar Link	pending
rna-20240930xex312.htm	Edgar Link	pending
rna-20240930xex321.htm	Edgar Link	pending
rna-20240930xex322.htm	Edgar Link	pending
rna-20240930xexx311.htm	Edgar Link	pending
Show.js	Edgar Link	pending
rna-20240930_def.xml	Edgar Link	unprocessable
rna-20240930_lab.xml	Edgar Link	unprocessable
rna-20240930_pre.xml	Edgar Link	unprocessable
rna-20240930_htm.xml	Edgar Link	completed
FilingSummary.xml	Edgar Link	unprocessable
rna-20240930_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RNA
Avidity Biosciences, Inc. Stock $rna

2024 Q4 Form 10-Q Financial Statement

#000159990124000186 Filed on November 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RNA Avidity Biosciences, Inc. Stock $rna

2024 Q4 Form 10-Q Financial Statement

#000159990124000186 Filed on November 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RNA
Avidity Biosciences, Inc. Stock $rna